Rasagiline-induced serotonin syndrome

Movement Disorders

Volumn 26, Issue 4, 2011, Pages 766-767

  Fernandes, Carl ^a   Reddy, Prashanth ^b   Kessel, Belinda ^c  

^a ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c Princess Royal University Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; RASAGILINE;

AGED; AGITATION; BLOOD PRESSURE; BRAIN ATROPHY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; LETTER; PARANOIA; PARKINSON DISEASE; PRIORITY JOURNAL; REHABILITATION CENTER; SEROTONIN SYNDROME; TOTAL KNEE REPLACEMENT;

AGED; FEMALE; HUMANS; INDANS; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; SEROTONIN SYNDROME;

EID: 79955004390     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23649     Document Type: Letter

References (7)

1. Isbister GK, Buckley NA. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol. 2005; 28: 205-214.
2. Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust. 2007; 187: 361-365.
3. Katzung GB. Basic and Clinical Pharmacology. 10th ed. New York, NY: McGraw-Hill; 2007: 267.
4. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991; 148: 705-7134.
5. Chen J, Swope D, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. J Clin Ther. 2007; 29: 1825-1849.
6. Thebault J, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy. 2004; 24: 1295-1305.
7. Guay D. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am J Geriatr Pharmacother. 2006; 4: 330-346.